Introduction
============

Tissue Fibrosis
---------------

Tissue fibrosis is the formation of excess fibrous connective tissue in a reparative or reactive process. It is usually observed after tissue injury in the lung, liver, heart, skin, eyes, and other organs. Some fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), can even lead to systemic progressive fibrosis and death ([@B125]; [@B61]).

The development of tissue fibrosis is generally sustained and progressive. At present, almost all kinds of fibrosis have no effective treatment, and the existing treatment can only improve the quality of life or prolong the life of patients to a limited extent. Therefore, it is urgent to find new precise signaling pathways or molecules participating in tissue fibrosis, and to explore new therapeutic strategies for tissue fibrosis in order to control the progressive development of the disease and even cure the disease. The S1P (sphingosine 1-phosphate) signaling pathway has become a hot spot in the research of fibrosis mechanisms in recent years because it is involved in the development of fibrosis. In many *in vitro* or *in vivo* experiments, inhibitors of this signaling pathway have been proven to effectively inhibit the development of multiple types of fibrosis, which provides a new thought for the treatment of fibrosis and the related diseases.

Signaling Pathways Mediated by S1P
----------------------------------

In recent years, the role of lipid in intercellular signal transduction has attracted increasing attention. The sphingomyelin (SM) signaling pathway is one of the main lipids of interest, which is involved in many activities of cells and organs, including cell survival, proliferation, differentiation, and diseases, such as cancer, infection, neurodegenerative disorders, and fibrosis.

The metabolic pathway of the SM signaling pathway is shown in Figure [1](#F1){ref-type="fig"}. In several mammalian cells, sphingomyelinases (SMase) catalyze SM to produce ceramide (Cer), while ceramidases (CDase) catalyze Cer to produce sphingosine (Sph), and S1P can be generated by two isoforms of sphingosine kinases (SphKs), sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2). At the same time, S1P can also be transformed into S1P phosphatase (S1PP) by intracellular Sph ([@B73]). After it is generated, S1P is secreted outside the cell by S1P transporter or degraded as ethanolamine phosphate and hexadecanal by S1P lyase (S1PL) rather than accumulating in cells under normal circumstances ([@B109]). S1P receptors (S1PRs, lysophospholipid receptors) are a kind of G protein coupled receptors, which have five different subtypes: S1P~1-5~. S1PRs are located in different tissues. For example, S1P~1~, S1P~2~, and S1P~3~ are widely expressed in multiple tissues; however, the expression of S1P~4~ is limited to lymphatic and hematopoietic tissues, and S1P~5~ is expressed in the central nervous system. Through binding to different receptors, S1P regulates many physiological or pathological processes ([@B137]). At the same time, the expression of S1PRs is also regulated by S1P ([@B101]). S1P, as a downstream product of SM pathway, plays an important role in many life activities. This article focuses on the role of S1P and its signaling pathway, that is, the relationship between S1P, SphK, S1PRs, and S1PL, in fibrosis of the lung, liver, heart, and other tissues (summarized in Table [1](#T1){ref-type="table"}) and the value of their clinical application.
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Overview of the role of S1P and the related signaling pathway in different types of fibrosis models.

  Organ/Tissue      Model                                                    Receptor(s)   SIP    Other sphingolipid or enzyme             Effects                                                                            Reference
  ----------------- -------------------------------------------------------- ------------- ------ ---------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------
  Lung              IPF patients                                             --            ↑      S1PR2↑, S1PR3↑, S1PL↑, SphK1↑, SphK2--   α-SMA ↑, activation Smad3 and RhoA-GTP, oxidative stress↑, TGF-β1↑, FN↑            [@B77]; [@B39], [@B41]; [@B42]
                    Normal human lung fibroblasts                            1--5          ?      ?                                        α-SMA --, ECM synthesis↑, activating PI3K/Akt and ERK1/2 signaling                 [@B112]
                    Human lung fibroblasts WI-38                             1, 2, 3       ↑      SphK1↑                                   α-SMA ↑, FN↑                                                                       [@B53]
                                                                                                                                                                                                                              [@B124]
                    Mice                                                     2, 3          ↑      SphK1↑, SphK2--, S1PL↑                   α-SMA ↑, FN↑                                                                       [@B53]; [@B77]; [@B39], [@B41]; [@B42]
  Liver             Hepatic myofibroblast                                    1, 2, 3       ↑      SphK1↑, SphK2--                          α-SMA ↑, Col I↑, Col III↑                                                          [@B65]
                    HSCs                                                     1, 2          ↑      SphK1↑                                   α-SMA ↑, Col I↑, Col III↑                                                          [@B114]; [@B16]
                    LX-2 cell line                                           1, 2, 3       ?      SphK1↑                                   α-SMA ↑, Col I↑, Col III↑, HYP↑, FN↑                                               [@B67]; [@B128]
                    Liver cancer patients                                    1, 2, 3       --     SphK1↑, SphK2--, SPNS2↑                  α-SMA ↑                                                                            [@B103]
                    Mice                                                     1, 2, 3       ↑/--   SphK1↑, SphK2--, S1PL--/↓\|, ASMase↑     α-SMA ↑, FN↑, TGF-β↑, Ang1↑, CD31↑, Col I↑, Col III↑, cell migration↑, HuR mRN↑a   [@B62]; [@B52]; [@B35]
                                                                                                                                                                                                                              [@B44]; [@B63]; [@B141], [@B142]; [@B26]; [@B19]; [@B50]; [@B129]
  Heart             Cardiac fibroblasts                                      1, 2, 3       ↑      SphK1↑, Cer↓, Sph↑                       Col ↑, IL-6↑, MMP-9↑, α-SM↑a, TGF-β↑                                               [@B46]; [@B70]; [@B7]
                    Mice                                                     1             ?      ?                                        ANP↑, BNP↑, Col I↑, α-SM↑a, CD31↑, ERK↑, IL-6↑                                     [@B86]
  Skeletal muscle   Murine C2C12 myoblasts                                   2, 3, 4       ↑      SphK1↑, SphK2--, S1PR3↑, Cer↑, Sph--     α-SMA ↑                                                                            [@B12]
  Kidney            Mice                                                     ?             ↑      SphK1↑                                   ECM↑, Col IV↑, FN↑, Mcp-1↑                                                         [@B127]; [@B138]
  Gluteal muscle    Gluteal muscle contracture (GMC)                         ?             ↑      ?                                        α-SMA ↑, cell Proliferation↑, TGF-β↑, PAI1↑                                        [@B148]
  Eye               Primary human retinal pigmented epithelial (RPE) cells   1, 2, 3, 5    ?      SphK1↑, SphK2↑                           α-SMA ↑, PAI1↑, HSP47↑                                                             [@B116]

↑, upgrade; ↓, downgrade; --, unchanged; ?, unmeasured.

In recent years, several studies have shown that some small molecular lipids, such as lysophosphatidic acid (LPA) ([@B149]) and S1P ([@B81]), are upgrade in the occurrence of diseases, such as cancer, inflammation, and tissue fibrosis. S1P is a naturally bioactive sphingolipid. S1P in plasma is mainly derived from red blood cells and activated platelets, which lack S1PL ([@B143]), or are phosphorylated by SphK1 ([@B126]). A variety of cells, including red blood cells, platelets, macrophages, mast cells, and endothelial cells, have been confirmed to be involved in the synthesis of S1P and secret S1P into the blood ([@B122]). S1P in blood is usually not dissociated but is closely bound up with albumin and high-density lipoprotein (HDLP) in plasma ([@B132]). A study has shown that the half-life of S1P in mouse plasma is only 15 min, which indicates that it has a rapid enzymatic reaction in the plasma, and S1PP and/or S1PL plays an important role in the reaction ([@B83]). S1P maintains a high level (1--2 μM) in the blood, implying that there is an efficient S1P production source in cells to maintain a high level of S1P ([@B99]). However, the concentrations of S1P in lymphatic tissues are relatively low (\<0.2 μM). The concentration gradient between blood and lymph may be related to the regulation of the immune cell transportation between the body circulation and the lymphoid tissue ([@B27]), and the difference of concentration may be a key factor in the migration of fibroblasts and cancer cells ([@B23]).

In recent decades, functions of S1P have been determined by several studies under normal physiological conditions. In general, there are two main functions. Firstly, S1P acts as an intracellular second messenger involved in regulating cell proliferation and inhibiting apoptosis by binding to the receptor S1PRs ([@B94]), whose function will be described in detail later in this article. Secondly, it becomes a regulator after translating out of cells regulating the cytoskeleton remodeling and cell migration, angiogenesis, and vessel maturation, the immune and lymphatic cell transport, and inflammation and malignant transformation ([@B38]; [@B21]; [@B72]; [@B11]; [@B34]; [@B90]).

Sphingosine 1-phosphate is widely assumed to play a protective role in the vascular system and tissues at the physiological level, while the abnormal activation of the S1P associated signaling pathway usually leads to fibrosis, cancer, and vascular dysfunction ([@B25]; [@B8]), and S1P plays an important role in promoting fibrosis, apoptosis, inflammation, and migration in these cases ([@B113]).

Recent studies have shown that S1P plays a crucial role in tissue fibrosis ([@B92]; [@B106]), and the tissue and/or plasma concentrations of S1P are associated with a variety of fibrosis factors, including transforming growth factor β (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF) ([@B104]). Both intracellular and extracellular S1P are reported to be involved in fibrosis activities. The increase of S1P in peripheral blood is seen in a variety of fibrosis-related diseases, and the use of anti-S1P antibody to neutralize S1P can effectively reduce TGF-β-mediated collagen production ([@B70]). In addition, a study indicates that intracellular and extracellular S1P affect cell growth and survival through different pathways ([@B87]). Studies have also indicated that S1P-mediated autophagy may be one of the pathways in the process of fibrosis ([@B121]), which is further described later in this article. In general, studies about the role of S1P in fibrosis have mainly focused on the effect of the secretion of key cytokines and the accumulation of extracellular matrix (ECM) after apoptosis, external chemical stimulation or hereditary diseases in cells or tissues.

Sphingosine kinase exists in a variety of cells with two types of isoforms, SphK1 and SphK2, and catalyzes the formation of S1P ([@B2]) studies show that S1P is synthesized entirely by SphK *in vivo* and plays an important role in life activities ([@B79]; [@B114]). At present, the role of SphK1 in tissue fibrosis is clearer, while the studies on SphK2 are relatively few. SphK1 and SphK2 are located in different subcellular structures. SphK1 is mainly located in the cytoplasm and can be activated by a variety of agonists, including tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF), then transferred to the plasma membrane to convert the Sph to S1P ([@B117]). Conversely, SphK2 has the effect of inhibiting cell growth and promoting apoptosis ([@B43]).

Sphingosine 1-phosphate receptors are important participants in many life processes. S1P~1~ plays an important role in angiogenesis in the embryonic period ([@B68]), and its function in the regulation of blood pressure in adult individuals has also been confirmed ([@B98]), and S1P~2~ is essential for the morphogenesis of zebrafish hearts ([@B56]). *In vivo*, the expression of S1PRs is regulated by many factors and cytokines. TGF-β1 has been proven to be an effective regulator to the expression of S1PRs ([@B20]). Using the supernatant of apoptotic cells to stimulate human macrophages can increase the expression level of S1P~1~ in macrophages ([@B131]). A growing body of evidence support that S1PRs play an important role in profibrosis in a variety of cells ([@B106]). A study, using the model of S1PR2 null mice or S1PR3 and S1PR2 double null mice, finds that the activity of Rho which is closely related to fibrosis, decreases significantly in these mouse embryonic fibroblasts ([@B45]). After inhibiting the expression of S1PR2 and S1PR3 genes *in vitro*, the differentiation of myofibroblasts is inhibited, and the study also localizes S1PR2 and S1PR3 on the cell membranes ([@B53]).

In order to combine with and activate S1PRs, a large amount of S1P needs to be secreted out of the cells by the transporters. This "inside-out-signaling" process involves the synthesis and transport of S1P in the cells and the activation of different kinds of S1PRs in the autocrine and paracrine signals in mammalian cells ([@B119]). At present, confirmed S1P transporters are mainly a variety of ATP-binding cassette (ABC) transporters, which exist in a variety of cell lines ([@B78]; [@B102]; [@B118]). In addition, spinster homolog 2 (Spns2) may be a special S1P transporter in different tissues ([@B33]; [@B82]; [@B85]).

Sphingosine 1-phosphate lyase is a key enzyme degrading S1P into the terminal molecule: hexadecenal and ethanolamine phosphate *in vivo* and *in vitro*, thereby controlling the concentrations of S1P \[9\]. Many experiments have demonstrated that activation of S1PL is involved in a variety of stimulation, such as bacterial endotoxin lipopolysaccharide (LPS) and radiation exposure ([@B148]; [@B9]).

The Relationship Between the S1P Signaling Pathway and Tissue Fibrosis
======================================================================

Pulmonary Fibrosis
------------------

Pulmonary fibrosis is a lung disease characterized by alveolar epithelial damage and accumulation of myofibroblasts, which are caused by a variety of factors, such as infections, inflammation, radiation exposure, and environmental pollutants ([@B136]). In recent years, treatment of mice with bleomycin has been used to establish a model of lung fibrosis in mice. In addition, S1PR agonists, such as fingolimod (FTY720), are also often used in the construction of *in vitro* models of pulmonary fibrosis, because they can induce differentiation of lung fibroblasts to myofibroblasts under prolonged stimulation ([@B112]). We would introduce further the function of FTY720 in studies on fibrosis diseases in later part of this article.

Idiopathic pulmonary fibrosis is a chronic and progressive lung disease, characterized by alveolar epithelial cell injury and areas of type II cell hyperplasia that results in the deposition of the ECM and the differentiation of fibroblasts to myofibroblasts ([@B108]). At present, there is no effective treatment for IPF except lung transplantation, and the average of survival only 3--5 years after diagnosis ([@B84]). Although the molecular and cellular mechanisms of IPF are not completely understood, several factors have been identified to be involved in the progression of IPF, such as reactive oxygen species (ROS) ([@B133]). S1P and the signaling pathway have been recently shown to promote the pathogenesis underlying IPF. A study showed that the S1P in bronchoalveolar lavage fluid (BALF) and serum of IPF patients increased significantly compared with the control group by microarray analysis of human peripheral blood mononuclear cells. Similarly, the increased expression of S1P, SphK1, and SphK2 was negatively correlated with lung function and survival rate ([@B77]). Also, it was demonstrated that the main pathological feature of IPF patients is cell proliferation, but not apoptosis and autophagy, which may be due to the high level of S1P inhibiting the pro-apoptosis effect caused by Cer ([@B105]). Therefore, inhibition of the formation of S1P may be an effective treatment for reducing the proliferation of fibroblasts in IPF patients.

In addition, results provided direct evidence that SphK1 may become a new type of target for treating pulmonary fibrosis. TGF-β is an important factor during the progress of pulmonary fibrosis, and S1P signaling pathways may be involved in the process of pulmonary fibrosis promotion by TGF-β. A previous study showed that the level of S1P regulated by TGF-β is also affected by the expression of SphK1 in lung fibrosis ([@B53]). SphK1 knockout or inhibiting SphK activity can reduce the expression of S1P and the secretion of TGF-β in cells, which can also reduce bleomycin-induced mouse pulmonary fibrosis ([@B39]). Conversely, the preconditioning of anti-TGF-β antibody can inhibit the expression of S1PL mRNA and protein induced by TGF-β in human lung fibroblasts, which indicates that, in pulmonary fibrosis, the role of S1P and its signaling pathways also depends on the level of TGF-β ([@B42]). In the TGF-β1 induced WI-38 cell fibrosis model, TGF-β1 activates SphK1 and leads to the Rho-associated myofibroblast differentiation in fibrosis ([@B53]). SphK1-deficient mice were protected against bleomycin-induced pulmonary fibrosis, and the expression of SphK1 protein increased in the lung tissues of IPF patients compared with the control group ([@B40]).

Sphingosine 1-phosphate receptors are also closely related to the development of lung fibrosis. WI-38 cells can express S1P~1~, S1P~2~, and S1P~3~ receptors *in vitro* ([@B124]). S1P can regulate pulmonary vascular permeability through S1P~1~, exogenous S1P, or S1P~1~ agonist activates S1P~1~ to mediate cytoskeletal rearrangements, promote intercellular adhesion and tight junction formation, enhance endothelial barrier function, and promote the development of fibrosis in endothelial cells. *In vitro*, the S1PR agonists such as S1P, FTY720-P, and TGF-β1 do not induce the expression of the myofibroblast marker α-SMA, but all can effectively stimulate the ECM synthesis and increase the expression of CTGF and other fibrosis markers. These results indicated that, different from TGF-β1, S1PR agonists activate PI3K/Akt and ERK1/2 signals, but not Smad2/3 signals, to mediate ECM synthesis, that is, S1PR agonists stimulate human pulmonary fibrosis by stimulating S1P~1~ and S1P~2~ in a Smad independent pathway ([@B112]). Further studies have shown that short-term stimulation (24 h) of S1P~1~ agonists, such as FTY720 and AUY954, can enhance the integrity of the vascular endothelial barrier, reduce vascular leakage caused by injury, and protect the body. However, prolonging exposure time in these S1P~1~ agonists (\>7 days) can aggravate mice pulmonary fibrosis and vascular permeability, which is induced by bleomycin ([@B100]; [@B110]). This effect requires further confirmation in *in vivo* experiments.

Sphingosine 1-phosphate lyase is also involved in fibrosis development. It was demonstrated that the expression of S1PL reduces TGF-induced differentiation of fibroblasts and inhibits the expression of S1PL by knocking out the gene attenuating pulmonary fibrosis, which is induced by bleomycin in mice. On the contrary, TGF-β increases the expression of S1PL in lung fibroblasts, and this effect can be inhibited by treating cells with anti-TGF-β antibody ([@B41]). Thus, S1PL may become a novel molecule to treatment lung fibrosis.

Autophagy has also been confirmed to be related to the process of lung fibrosis. [@B41] structured a mouse model of partial deletion of S1PL gene and found that those mice reacted more violently to bleomycin-induced pulmonary fibrosis and the expression of autophagy-related markers, LC3 and beclin 1, are reduced when their lung S1P increases; however, the overexpressed S1PL can reduce S1P and increase the level of autophagy-related markers.

In general, S1P, SphK, S1P~1,2~, and S1PL have been proven to be involved in the development of pulmonary fibrosis, and the role it plays is clearer. Reducing the formation of S1P and inhibiting the activity of SphK and S1PL can effectively weaken the formation or development of fibrosis in both *in vivo* and *in vivo*, while the effects of using S1P~1~ and S1P~2~ agonists are related to the treatment time. At present, most of the pulmonary fibrosis diseases lack an effective treatment, and the role of S1P and its signaling pathway in pulmonary fibrosis is likely to be a potential therapeutic strategy.

Liver Fibrosis
--------------

Liver fibrosis is a chronic progressive liver disease characterized by the accumulation of ECM protein ([@B10]). It is a precursor of cirrhosis and even liver cancer caused by chronic liver disease, multiple injuries, or dysfunctional wound healing ([@B51]). The development and remission of hepatic fibrosis is believed to be a reversible process ([@B51]). At present, liver transplantation is the only treatment for terminal liver disease, but it is limited by the availability of donor organs and the risk of lifetime immunosuppression ([@B71]). Bile duct ligation (BDL) and inducing chronic low-level inflammation and necrosis of the liver by CCl4 are often used in establishing hepatic fibrosis models, and the latter is considered to be closer to the morphological and pathophysiological state of human liver fibrosis ([@B74]).

Although the research on the etiology and molecular mechanism of liver fibrosis has made great progress in the past 20 years, there is still no effective treatment strategy. There is a comprehensive source of myofibroblasts in the liver, including hepatic stellate cells (HSCs) and bone marrow-derived mesenchymal stem cells (BMSCs) ([@B97]). At the early stages of the liver fibrosis, liver injury leads to the recruitment of inflammatory cells, which release many factors causing activation of HSCs. Activated HSCs turn into a myofibroblast-like phenotype, which gain contractile, proinflammatory, and fibrogenic properties and then release proteins leading to the accumulation of ECM ([@B31]; [@B144]). PDGF is the most effective mitogen and chemotactic factor of the HSCs released factors ([@B91]). Therefore, finding a way to block HSC activation may become an effective way to search for antifibrotic drugs. Stimulating liver regeneration may be another treatment strategy for liver diseases, and the use of HSCs is considered to be one of the potential therapeutic methods. In the advanced period of liver fibrosis, liver function is destroyed and irreversible cirrhosis develops ([@B95]).

In recent years, since S1P has been found to regulate the expression level of a variety of ECM in the process of liver fibrosis, it is believed to play an important role in the process of liver fibrosis by affecting the expression of various fibrotic markers ([@B62]). HSCs have a steady state of circulation in the body, and the gradient distribution of S1P in the tissues and lymph is identified as a key regulator of the cycle ([@B75]). An *in vitro* study of CCl4-induced hepatic fibrosis shows that S1P promotes the development of liver fibrosis by participating in HSCs activation and differentiation to myofibroblasts ([@B35]). At the same time, reducing the S1P liver tissue:lymph gradient by inhibiting the migration of HSCs can also preserve the liver and reduce subsequent fibrosis, which may be a new strategy in the treatment of hepatic fibrosis in future ([@B50]). An animal experiment shows that BMSCs in mice migrate to the damaged liver and activate myofibroblasts induced by S1P and its receptors after the liver is damaged ([@B141]). The movement of BMSCs has also been found to be regulated by the S1P concentration gradient in the liver and bone marrow ([@B63]). Hepatic fibrosis is a sign of performance during the pathogenesis of liver cancer. Recently, a cohort study showed that S1P may be one of markers to estimate the severity of liver disease ([@B6]).

S1P~1~ and S1P~3~ are considered to be the two major S1PRs that play a key role in liver fibrosis. Exogenous S1P increases the expression of SphK1 and S1P~1~ and S1P~3~ in human HSCs LX-2 cells ([@B67]). This phenomenon also occurs in human fibrosis liver samples ([@B65]). It has been shown that a potent agonist for four of the five S1PRs (S1P~1,3-5~), FTY720-P, plays a role in suppressing cell proliferation and migration in cultured HSCs by inhibiting the signal pathway between S1P and PDGF ([@B16]). A study found that S1P-induced myofibroblasts migration from plasma to the liver injury depends on the role of S1P~3~ ([@B62]). A study showed that the level of S1P in the liver is closely related to the expression of angiogenesis markers Ang1 (angiopoietin) mRNA. In addition, the S1P~1~ and S1P~3~ antagonists block the upregulation of Ang1 and alleviate the degree of liver fibrosis in the damaged liver ([@B142]). HuR (human embryonic lethal abnormal visual protein) is a key post-transcriptional regulator of gene expression. In recent years, increasing attention has been paid to the role of HuR in fibrosis ([@B5]; [@B134]). A study has shown that there is a positive feedback mechanism between HuR and S1P~3~, which can affect the vitality of BMSCs and further affect the process of fibrosis ([@B19]). However, although the expression of S1P and S1P~1~ and S1P~3~ is reported to play a role in promoting fibrosis in liver fibrosis models of BDL and CCl4 stimulation ([@B142]; [@B128]), S1P~1~ was associated with the formation of angiogenesis and granulation tissue in another report ([@B140]), and in a study of chronic injury and cholestasis in mice, S1P~1~ was found to be highly expressed in vascular endothelial cells and then reduce fibrosis by stimulating hepatic regeneration ([@B26]). These different results may be caused by different models of selection and may also be due to the removal of a variety of different kinds of liver cells, which lead to different stress responses. Therefore, in future studies, more specific experiments are needed to confirm the different roles of S1P and S1PRs in the process of fibrosis through different cells.

Studies about S1PRs and the differentiation of BMSCs are also contradictions. S1P~1~ and S1P~3~ are shown to be involved in the differentiation of BMSCs to myofibroblasts in mice ([@B141]). While they seem to inhibit the expression of collagen in human BMSCs ([@B20]). The above results from different laboratories may differ depending on the different species or models, but the direct mechanism of S1PRs in liver fibrosis requires further experimentation to verify, and its application in the treatment of liver fibrosis remains to be discussed.

The role of S1P~2~ in the process of fibrosis is also worthy of attention. The expression of S1P~2~ in the fibrosis case group and the control group is not significant in many experiments ([@B63]). However, in another study of the same model, the S1P~2~ gene knockout mice or those injected with S1P~2~ antagonist JTE-013 expressed low Rho kinase activity after BDL, and the expression of S1P~2~ mRNA increases after the operation in the wild-type mice ([@B47]). In addition, a recent study confirmed the role of S1P~2~ in the liver injury in a cholestasis mouse model ([@B129]). The hepatic fibrosis induced by CCl4 or dimethyl nitrosamine decreases in the S1P~2~^-/-^ mice ([@B44]), and the result of a population study shows that the expression of S1P~2~ decreases in patients with liver fibrosis ([@B65]). These results suggest that S1P may play a role in fibrosis through S1P~2~ in the process of fibrosis.

Previous studies have shown that the S1P/SphK signaling pathway is involved in liver fibrosis depending on TGF-β. A recent study provided evidence that production of collagen I is increased by SphK1 in human liver myofibroblasts after TGF treatment ([@B137]). Recently, Melatonin it was found to be involved in protecting fibrosis in different organs, including the liver ([@B30]). A study used CCL4 to establish a liver fibrosis model and found that melatonin treatment not only reduces the degree of fibrosis, but also inhibits the SphK1/S1P signaling pathway both *in vitro* and *in vivo*, thus confirming the hypothesis ([@B35]).

In addition, the effect of intracellular S1P in liver fibrosis is closely related to the role of transporter Spns2 ([@B137]). S1P may be transported out of cells by Spns2 in the process of liver fibrosis, and then combines with S1PR to promote the liver fibrosis ([@B103]). All kinds of apolipoprotein play a similar role in bile and peripheral blood, and apoM is a kind of protein mainly derived from hepatocytes, in which the spatial structure determines that its main function is to carry lipid signal molecule S1P to bind with S1P~1-5~ on the membrane ([@B21]; [@B55]; [@B36]). Research shows that apoM is the main carrier of S1P in plasma, and the secretion of apoM in the liver and other organs is correlated with the amount of S1P in the blood ([@B80]). A recent animal experiment has suggested that apoM is associated with S1P signaling pathways in liver fibrosis ([@B26]). Both S1P and apoM are involved in inducing the expression of liver receptor homologous 1 (LRH-1), suggesting that there might be a bile acid metabolic pathway between the two molecules ([@B89]). However, whether apoM is directly associated with S1P in plasma and secretion into bile needs to be explored further in the future.

In summary, the liver, as the most important metabolic organ in the body, has extensive blood flow and a complex metabolic system. Different from the lung, the concentration gradient of S1P in circulation and tissue seems to be more closely associated with liver fibrosis than the concentration of S1P, which may be due to the origin of macrophages, HSCs and BMSCs in the liver. The effect of the associated transporters in the S1P signaling pathway also contributes to the promotion of liver fibrosis. However, the role of S1PRs in liver fibrosis remains controversial and requires further study. In addition, the expression of TRAF2, melatonin, and other molecules are also involved in the regulation of liver fibrosis by S1P and its signaling pathway.

Cardiac Fibrosis
----------------

Heart failure is one of the most important health problems worldwide. According to statistics, there are approximately 23 million heart failure patients all over the world ([@B3]), and the incidence and mortality of heart failure have been gradually increasing for several decades among people aged more than 65 years ([@B22]). Myocardial fibrosis is one of the main manifestations of the development of heart failure. It is mainly due to the secondary diseases caused by ischemia-reperfusion injury or other causes. Fibroblasts can change from static state to proliferation, migration, and secretory state in the condition of myocardial infarction, which changes the phenotype to become myofibroblasts, and then expresses contractile proteins, including α-SMA, finally leading to myocardial fibrosis ([@B54]). At present, there is no effective treatment for myocardial fibrosis ([@B88]). Therefore, studying its development process and treatment is the key to finding a treatment for heart failure.

In the cardiovascular system, the SM signaling pathway is considered to be a signal-regulated pathway in pathological conditions. A recent review article on the role of S1P in myocardium impairment suggested that a series of signaling pathways induced by S1P is the protective factor of myocardial ischemia reperfusion and oxidative injury, and HDL plays a role in promoting it ([@B48]). However, the relationship between the protective effect and myocardial fibrosis is not mentioned in the article. Interestingly, both *in vitro* and *in vivo* experiments suggest that S1P is not involved in the process of mediating the hypertrophy of myocardial cells in neonatal mice ([@B107]; [@B120]). However, Philippe's study suggests that S1P mediates myocardial cell hypertrophy in mice through S1P~1~ ([@B96]). A study has shown that S1P plays an important role in the regulation of cardiac fibroblast migration and proinflammatory response in myocardial hypoxia ([@B46]). Relaxin (RLX), a kind of peptide hormone causing a physiological cardiac effect, is the key regulation factor of ECM remodeling in many tissues ([@B29]). A study using immature primary cardiac myocytes isolated from neonatal mice and mice heart myofibroblasts H9C2 found that RLX could mediate SM metabolism, SphK1 activation, and the production of S1P in cardiac myocytes. Meanwhile, the production of S1P mediated by RLX is the key to ECM remodeling in cardiac myocytes, and it provides a new therapeutic strategy for preventing cardiac fibrosis and promoting myocardial regeneration ([@B32]). However, studies researching the role of S1P in cardiac hypertrophy and fibrosis remain insufficient in both *in vitro* and *in vivo*, and the models are not consistent, and the model, which uses S1P or the interrelated molecules to induce myocardial hypertrophy and fibrosis directly, is likely to change the metabolic rate of other molecules in the pathway, resulting in incorrect judgment of the effects of S1P. Thereby, these conclusions suggest that using S1P and some molecules in its pathway may be a potential method for the treatment of myocardial hypertrophy and fibrosis, while, due to the contrary results, the mechanism still needs to be further confirmed in *in vivo* experiments, and the correlation between these phenomena and human heart fibrosis warrants further exploration.

The expression of SphK1 in cardiac fibroblasts can affect the degeneration and fibrosis of cardiomyocytes. *In vivo* study showed that SPHK1-transgenic mice present myocardial degeneration and fibrosis at high levels of SphK1 (SphK1 activity increased 20 times), while this is not observed at lower SphK1 levels (SphK1 activity increased five times) ([@B120]). However, there is an opposite conclusion: the expression of SphK1 in cardiac fibroblasts is much higher than that in cardiac myocytes. Under normal conditions, SphK1 is necessary for the proliferation of cardiac fibroblasts, but in the case of myocardial hypoxia, SphK1 plays an anti-inflammatory role and inhibits the occurrence of cardiac fibrosis. Therefore, it plays a dual regulatory role in cardiac physiology and pathology ([@B46]). The above two studies have shown that SphK1 does play a regulatory role in the process of cardiac fibrosis. However, this effect may be related to the activity and expression of SphK1. Therefore, the mechanisms of SphK1 in cardiac fibrosis require further study.

S1P~1~, S1P~2~, and S1P~3~ are expressed in the heart. There are differences in the distribution of different subtypes of S1PRs in different types of cardiac cells: the main distribution of S1PR in cardiomyocytes is S1P~1~, while the expression of S1P~2~ and S1P~3~ are low ([@B145]; [@B58]), and S1P~3~ is mainly distributed in fibroblasts ([@B57]). A study shows that S1PRs can regulate the ion channel and mediate myocardial self-protection through ischemic preconditioning, so it is a key molecule to regulate the function of the myocardium ([@B49]). A mouse experiment shows that the expression of S1P~1~ is upregulated during myocardial hypertrophy and could be overexpressed in interleukin (IL)-6 secretion depending on the Ang II-AT1, causing cardiac hypertrophy and fibrosis, and affecting the systolic function of the heart. However, this phenomenon occurs only in the proliferative fibroblasts/myocytes of the mouse heart, but not in the cardiomyocytes ([@B86]). *In vivo*, the activation of S1P~2~ and S1P~3~ can weaken the ischemia-reperfusion injury of myocardium. The mechanism may be that S1P can affect ventricular fibrosis through S1P~3~, and then mediate fibroblast differentiation into myofibroblasts, which may be a therapeutic strategy to treat fibrosis after cardiac physiology and pathology injury ([@B76]; [@B7]). Additionally, knocking out S1P~3~ in the heart cells can inhibit the fibrosis in mice with high expression of SphK1 through a Rho- and Smad3-dependent signaling pathway ([@B120]). FTY720 can also reduce the formation of myocardial fibrosis by inhibiting oxygen free radicals to produce strong anti-inflammatory and antioxidant properties, thus reducing the death of cardiomyocytes ([@B4]). A study using the heart transplantation mouse model suggests that FTY720 is an effective ischemic preconditioning agent, which can reduce apoptosis, inflammation, oxidative stress, and myocardial fibrosis in the model ([@B1]).

In recent years, the role of S1P in the relationship between autophagy and myocardial damage has become a topic of concern. As in other tissues, autophagy after myocardial damage is beneficial to the organism in most cases, but in some cases, it also causes damage to the organism. A study suggests that autophagy-related survival is regulated by SphK1 to some extent, while autophagy-related deaths are regulated by Cer ([@B59]).

In a comprehensive sense, S1P, S1PR, and SphK are related to the expression of several factors in many interrelated fibrotic pathways in the process of cardiac fibrosis and play a role in the pathogenesis and development of fibrosis together. However, the molecular mechanism of the relationship between S1P and cardiac fibrosis is unclear, as is the promotion or inhibition of cardiac fibrosis in different conditions. Therefore, whether these molecules in the pathway can be used in future as a target for the treatment of cardiac fibrosis still require further study *in vitro* and *in vivo*.

Other Tissue Fibrosis
---------------------

Diabetic nephropathy, which usually leads to renal fibrosis, begins with hyperglycemia, which subsequently generates glucotoxicity in renal tubular epithelial cells. Later, like other fibrosis diseases, inflammatory cells are recruited and activated to produce a large number of inflammatory factors, such as monocyte chemoattractant protein 1 (MCP1) and TGF-βs, which are soon released into the interstitium, and fibrosis-related signal pathways are activated, resulting in the positive feedback to promote the production and accumulation of ECM. In particular, extracellular growth factors can stimulate the paracrine effect in renal fibrosis ([@B60]). A study has shown that S1P signaling may take part in the development of fibrosis in diabetic nephropathy ([@B138]). Living in the environment of hyperglycemia and oxidative stress for a long time activate SphK1 and increase S1P synthesis ([@B127]). Glucose stimulation increased the level of S1P in pancreatic islet cells under the action of SphK2, but the levels of Cer and Sph remained unchanged ([@B13]; [@B115]). A further study has shown that FTY720 selectively inhibits lymphocyte migration and alleviates ischemia-reperfusion injury after renal fibrosis by reducing the release of ECM and finally reduces the progression of glomerulosclerosis ([@B24]).

Gluteal muscle contracture (GMC) is also a chronic fibrotic disease caused by multiple etiologies, which is characterized by proliferation of fibroblasts and accumulation of collagen in the ECM of muscles ([@B146]). A recent study provided evidence that the level of S1P increased in the muscles of patients with GMC, and exogenous S1P stimulation can promote the proliferation of contraction band (CB) fibroblasts in a dose- and time-dependent manner, and also promote the expression of α-SMA, collagen, TGF-β1, and PAI-1 at mRNA and protein levels, which indicates that S1P plays several roles in the development of GMC ([@B147]). In addition, the SphK1/S1PR signaling pathway is also involved in the process of TGF-β-mediated skeletal muscle fibroblasts transforming into myofibroblasts and plays a role in profibrosis ([@B12]).

Sphingosine 1-phosphate and the related signaling pathway are also involved in ocular fibrosis. It can stimulate retinal pigmented epithelial cells converting into fibroblast-like cells. At the same time, S1P increases two markers of fibrosis, PAI-1 and HSP47 ([@B116]). Intravenous anti-S1P monoclonal antibody can inhibit choroid neovascularization and collagen deposition under the retina, suggesting that extracellular S1P plays an important role in ocular fibrosis ([@B18]). Therefore, the use of anti-S1P antibodies may be a therapeutic strategy for ocular fibrosis and exudative age-related macular degeneration by inhibiting the formation of profibrosis factors, angiogenesis, and retinal fibrosis, but research is still lacking regarding the role of S1PRs.

Dermal fibroblasts and myofibroblasts play an important role in the repair and remodeling of wounds. Due to the role of S1P and S1PRs in cell migration and their profibrosis effects, a study has suggested that they may have important clinical implications in trauma repair and abnormal wound healing ([@B130]). S1P~1~ and S1P~3~ have been shown to cooperate with TLR4 to promote the secretion of pro-inflammatory cytokines in endothelial and epithelial cells ([@B28]). An *in vitro* experiment demonstrated that TLR activation and S1P stimulation together regulate the inflammatory response in normal human dermal fibroblasts, which has been shown to induce pro-inflammatory cytokine production and myofibroblast differentiation as well as cell migration ([@B37]).

In general, S1P is up-regulated in the development of kidney, gluteal, ocular, and dermal fibrosis, and is thought to play a role in promoting fibrosis by interacting with other molecules, such as inflammatory factors, in these tissue fibrosis.

Clinical Application of S1P Signaling
=====================================

As mentioned earlier, extensive studies point out that the role of S1P in fibrosis comes from if it actives S1PRs through the actions of S1P in the context of autocrine or paracrine signaling or directly participates in the signal transduction in the cell.

Sphingosine 1-phosphate, which is secreted to the ECM, promotes fibrosis mainly through S1P~2~- and S1P~3~-mediated TGF-β and other signaling pathways in many organs or *in vitro* cell lines. Therefore, antagonizing S1P~2~ or S1P~3~ may be measurable interventions to prevent fibrosis. However, only little S1PRs antagonists have been used in clinic settings.

FTY720 was originally used as a kind of immunosuppressant, and it can induce a significant reduction of peripheral lymphocytes by inducing the lymphocytic closure in secondary lymphoid organs. In recent years, its role in fibrosis has gradually been taken more seriously. *In vivo*, FTY720 can be rapidly phosphorylated into FTY720-P, which shares structural homology to the natural ligand S1P, so that is highly affinity with S1P~1~ and S1P~3-5~ and can be combined with them ([@B15]). Therefore, FTY720 is widely used in fibrosis-related studies. For example, in the studies of fibrotic animal models, FTY720 plays a useful role in the treatment of fibrosis by reducing the inflammatory response or inhibiting the dysfunction of the microvascular endothelium ([@B66]). Clinically, it is used for oral treatment of relapsing multiple sclerosis because it can promote cell phagocytosis and the degradation of S1P, thereby antagonizing the role of S1P in cells ([@B14]). However, FTY720 is also used in the establishment of fibrotic models in both *in vitro* and animal experiments. Currently, it is believed that the phosphorylated form FTY720-P causes desensitization of the receptor, that is, cells or tissues exposed to FTY720-P for a long time are inactivated to S1P, showing a phenotype similar to the lack of circulating S1P or the treatment of S1PRs antagonists. Therefore, the clinical use of FTY720 should be very cautious and fully considered about its risk of prolonged treatment.

In the lung and cardiac fibroblasts, SphK1 mediates TGF-β-activated profibrosis to produce S1P. Then, those S1Ps are released out of cells to bind with S1P~2~ or S1P~3~, and finally promote fibroblast differentiation ([@B53]; [@B70]). In the meantime, inhibition of SphK1 may also play a role in inhibiting fibrosis by inducing fibroblast apoptosis ([@B93]). Therefore, the double-inhibition of SphK1 and the antagonistic effect of S1P~2~ and S1P~3~ may be effective means of reducing fibrosis.

However, some studies thinks that intracellular S1P is an anti-fibrotic molecule. Whether this effect is directly caused by S1P and then induces the change of Cer, or by the change of ratio between the two molecules remains to be further verified. Therefore, due to the potential protective role of S1P in cells, the molecular mechanism of SphK1 inhibitors to prevent fibrosis will become more complex.

In recent years, the role of dhS1P in fibrosis has been gradually concerned. Similar to S1P, dhS1P is catalyzed by SphK, while the expression of dhS1P is much lower than S1P *in vivo* and the function is not completely clear. DhS1P and S1P play different roles in the fibrosis by participating in different signaling pathways. The increased expression of S1P can promote the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) induced by TGF-β and then inhibit the degradation of ECM and promote the occurrence of fibrosis ([@B139]). DhS1P can stimulate the generation of matrix metalloproteinase 1 (MMP1), which induces the degradation of ECM and has the opposite biological function to S1P ([@B69]). The results from the study of fibroblast in patients with SSC also confirmed that dhS1P may be a potential drug for the treatment of fibrosis ([@B17]). However, both S1P and dhS1P are catalyzed by SphK, and all of them play a biological role by activating S1PRs. Therefore, further experiments are needed to determine how they play different roles in the process of fibrosis and whether they combine with the receptors, leading to different conformational changes of the receptor to activate different signals. It is possible to find a new intervention target for the treatment of fibrosis in this direction.

In addition, the different roles of inflammatory cells and those secreted cytokines in different stages of fibrosis are also noteworthy. For example, macrophages associated with inflammation and fibrosis plays an opposite role in lung inflammation (the early stages of fibrosis) and tissue remodeling (the late stages of fibrosis) ([@B64]). Several inflammatory factors, such as TNF-α, promote fibrosis through stimulating the synthesis of IL-1β and TGF-β1 in a variety of cells, including macrophages and fibroblasts ([@B123]; [@B135]) but inhibit collagen synthesis in myofibroblasts ([@B111]). However, there are relatively few studies on the different roles of S1P and the related signaling pathways in different stages of fibrosis. Therefore, it is necessary for us to better understand the role of each kind of cell, molecule, and element in the different stages of fibrosis and thus to improve the molecular mechanism of the inflammatory and proliferative responses to fibrosis, then better utilize the S1P and its signaling pathways in the treatment of fibrosis-related diseases.

In addition to drug therapy, S1P is also a potential biomarker of some diseases. In a study, S1P was considered to be a potential biomarker for judging the severity of liver diseases ([@B6]). However, due to the complexity and high cost during the measure of S1P at present, the clinical application cannot be realized in a short time. Therefore, it is necessary to explore an efficient, simple, and economical method of detecting S1P.

Conclusion
==========

At present, an effective treatment of fibrosis is still lacking. Once the fibrous tissue has formed, it is difficult to repair into normal tissue. Therefore, the studies on preventing or slowing down the development of fibrosis diseases and blocking the upstream biological processes before fibrogenesis offer better strategies for these kinds of diseases at present. A large number of *in vitro* and *in vivo* studies have shown that S1P and its signaling pathways are involved in the development of multiple tissue fibrosis. Through combining with different S1PRs, S1P may play different roles in different organs and models. SphK, S1PL, and several kinds of S1P transporters also take part in the process of fibrosis by regulating the synthesis, degradation, and transfer of S1P. At the same time, S1P and the related signaling pathways compose complex signaling networks with so many signal pathways, such as inflammation, apoptosis, and autophagy, and regulate the development of fibrosis. However, the mechanism of S1P and the related signaling pathways in fibrosis have not been fully elucidated, and they have different roles in different organs and species that require further study. In addition, the intervention of S1P and the related signaling pathways are potential treatments for fibrosis-related diseases, and S1P is also expected to become an effective biomarker of the severity of fibrosis diseases in the future.
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